ArticleBritish journal of clinical pharmacology2026
Population pharmacokinetic modelling revealed large variability in oromucosal absorption of Δ
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Effects of SativexNutrients · 2026Trial
- Review
- Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies.Diseases (Basel, Switzerland) · 2026Review
- Population pharmacokinetic modelling revealed large variability in oromucosal absorption of ΔBritish journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
aimCannabis-based medicines are gaining interest and being explored for new therapeutic indications, many of which commonly affect older medical patients. As most previous studies of the population pharmacokinetics of cannabinoids have been performed in healthy adults, this study aimed to investigate the population pharmacokinetics of Δ
methodsWe administered two fixed doses of Sativex® oromucosal spray to 20 patients, each dose consisting of two or three sprays (2.7 mg THC and 2.5 mg cannabidiol per spray), with a dosing interval of 4 h. Blood samples were collected for up to 8 h to obtain plasma concentration-time data for non-linear mixed-effects modelling. Population pharmacokinetic models were developed for THC and THC-OH sequentially, resulting in a combined parent-metabolite model.
resultsWe found a one-compartment model and a two-compartment model to be the best fits for THC and THC-OH, respectively, with apparent clearance of THC through conversion to THC-OH (765 L h
conclusionThe parent-metabolite model describes and quantifies the pharmacokinetics of oromucosally administered THC in older medical patients with poor appetite. The covariate analysis did not show any clinically significant effect on pharmacokinetic parameters of THC or THC-OH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.